Perfect Match: ALD acquires Fleetpool Group
Car subscription pioneer Fleetpool strengthens position under ALD umbrella ALD expands service offering with fully…
Month: October 2021
TopCV index of job seeker sentiment reveals light at the end of the tunnel as market confidence grows
LONDON (13th October 2021) — TopCV, the world’s largest CV-writing service, has revealed that UK…
prpl Foundation previews its prplWare CPE Software at BBWF in Amsterdam, October 13th and 14th, 2021
SANTA CLARA, Calif., October 13, 2021 – The prpl Foundation, an organization dedicated to carrier-grade…
Orbus Software to be Platinum Sponsor at 2021 Gartner IT Symposium Next Week
Held virtually this year, the Gartner IT Symposium will take place from October 18 to…
Bridge Alliance and TM Forum partner to simplify adoption of edge computing for global telecom industry
Collaboration will drive the advancement of industry standards on Open APIs for multi-access edge computing…
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS…
Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
80% overall survival rate at 24 months follow-up OSLO, Norway, Oct. 13, 2021 (GLOBE NEWSWIRE)…
Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
80% overall survival rate at 24 months follow-up Oslo, 13 October 2021: Ultimovacs ASA (“Ultimovacs”)…
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations LONDON and RALEIGH, N.C., Oct. 13,…
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Data on Tedopi®, BiCKI® and CLEC-1 programs being presented in three poster presentations – November…
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase
FOR INFORMATION Nicox to present at the OIS Glaucoma Virtual Innovation Showcase October 13, 2021…
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line…
Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome
Potential to revolutionise the current treatment paradigm and become the cornerstone therapy for patients with…
Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after…
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is…
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) − Enochian BioSciences, a company…
Travere Therapeutics Announces Transition of Chief Medical Officer
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH:…
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Study Approval Paves the Way for Trial Participants to Begin Taking Apabetalone CALGARY, Alberta, Oct….